Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Weight loss is a proven strategy to alleviate the severity of OSA. Eli Lilly’s clinical trials reveal that nearly half of Zepbound users experienced significant improvements, with some no longer ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity. Nearly half of clinical trial patients saw such ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

He now oversees Eli Lilly’s pipeline of incretin medications, including its blockbuster weight-loss drug Zepbound. Now, recent studies and clinical trials have found that these drugs also have ...

“Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity. Nearly half of the clinical trial patients saw such ...

“Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity. Nearly half of the clinical trial patients saw such ...